|
11 Dec 2022 |
Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH
|
|
11 Dec 2022 |
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
|
|
11 Dec 2022 |
Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
|
|
11 Dec 2022 |
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
|
|
11 Dec 2022 |
Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting
|
|
11 Dec 2022 |
Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
|
|
10 Dec 2022 |
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
|
|
09 Dec 2022 |
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
|
|
09 Dec 2022 |
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
|
|
09 Dec 2022 |
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
|
|
09 Dec 2022 |
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
|
|
09 Dec 2022 |
New Clinical Data For Zanidatamab In HER2+ /HR+ Metastatic Breast Cancer Presented Today At 2022 SABCS
|
|
09 Dec 2022 |
Cytovia Therapeutics Presents New Data on CD38-Targeted Flex-NK™ Bispecific Antibody at 2022 American Society of Hematology Annual Meeting
|
|
09 Dec 2022 |
UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa
|
|
09 Dec 2022 |
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
|
|
09 Dec 2022 |
Innovent Presents Phase Ib Clinical Data of IBI939 (Anti-TIGIT Monoclonal Antibody) in Previously Untreated PD-L1-selected NSCLC at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
|
|
09 Dec 2022 |
Innovent Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
|
|
09 Dec 2022 |
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer
|
|
08 Dec 2022 |
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
|
|
08 Dec 2022 |
Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET
|
|
07 Dec 2022 |
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
|
|
07 Dec 2022 |
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
|
|
07 Dec 2022 |
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
|
|
06 Dec 2022 |
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
|
|
06 Dec 2022 |
AltruBio Announces FDA Clearance of IND Application for ALTB-268, a Next-Generation Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis
|
